NCT05154994 2026-01-27
RESOLVE
University of Utah
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT04315233 2025-04-22
CHARGE
University of Utah
Phase 1 Recruiting
NCT04703920 2025-01-23
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT04315155 2020-10-28
BENEFIT
University of Utah
Phase 1 Withdrawn
NCT02142530 2018-01-25
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Massachusetts General Hospital
Phase 1 Completed
NCT02875002 2017-12-22
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Yale University
Phase 1 Withdrawn
NCT01075425 2016-04-15
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
Phase 1 Completed
NCT02532192 2016-01-06
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn